Evidence-based analysis at the intersection of global health, public policy, health economics, and pharmaceutical access. Written for professionals, policymakers, and anyone who wants to understand how health systems really work.
The relationship between geography and survival is not accidental. It is the cumulative result of decades of underinvestment, structural inequality, and a global health architecture that continues to prioritise the concerns of wealthy nations over the needs of those who bear the highest disease burden.
On pharmaceutical sovereignty, supply chain fragility, and what genuine access actually requires in the context of a continent that bears 25% of the global disease burden.
Cross-continental evidence that challenges assumptions about who is learning from whom — and what social prescribing research in Aberdeen revealed about models from Lagos.
A clear-eyed look at the metrics that shape healthcare decisions globally. Why QALYs are both indispensable and deeply flawed — and what this means for health systems in low- and middle-income countries.
UHC is the right goal. But the financing frameworks, workforce requirements, and political economy of getting there remain profoundly underestimated — particularly for countries that can least afford to get it wrong.
AMR is already the leading cause of death globally. In Africa, where antibiotic overuse and supply chain failures intersect, the situation is acute — and the policy response remains deeply inadequate.